GB2597284A — Use of cannabidiol in the treatment of seizures associated with multifocal epilepsy
Assigned to GW Research Ltd · Expires 2022-01-26 · 4y expired
What this patent protects
A cannabidiol (CBD) preparation for use in the treatment of seizures associated with multifocal epilepsy. The seizures can be tonic seizures. The CBD preparation can comprise greater than 95% (w/w) CBD and not more than 0.15% (w/w) tetrahydrocannabinol (THC). The CBD preparation …
USPTO Abstract
A cannabidiol (CBD) preparation for use in the treatment of seizures associated with multifocal epilepsy. The seizures can be tonic seizures. The CBD preparation can comprise greater than 95% (w/w) CBD and not more than 0.15% (w/w) tetrahydrocannabinol (THC). The CBD preparation can comprise greater than 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids comprising THC, cannabidiol C-1 (CBD-C1), cannabidivarin (CBDV), or cannabidiol C-4 (CBD-C4). The THC can be present as a mixture of trans-THC and cis-THC. The CBD preparation can be used in combination with other anti-epileptic drugs (AED). The AED can be clobazam, lamotrigine, zonisamide, or diazepam. The CBD can be isolated from cannabis plant material. The CBD can be present as a synthetic preparation. The CBD preparation can be used at a dose greater than 5 mg/kg/day. The dose of CBD can be 20, 25, or 50 mg/kg/day. A further aspect of the invention is a method of treating seizures associated with multifocal epilepsy comprising administering a CBD preparation to a subject.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.